Publication | Open Access
Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer
84
Citations
42
References
2021
Year
Our data provide a rationale for clinical evaluation of the therapeutic synergy of the PARPi olaparib and CDK4/6i palbociclib in BRCA<sup>mut</sup>/TNBCs with high Wnt signalling activation and high MYC expression that do not respond to PARPi monotherapy.
| Year | Citations | |
|---|---|---|
Page 1
Page 1